De Nunzio Cosimo, Salonia Andrea, Gacci Mauro, Ficarra Vincenzo
Department of Urology, Sant'Andrea Hospital, Sapienza University of Rome, 00185 Rome, Italy.
Department of Urology, University Vita-Salute San Raffaele, 20132 Milan, Italy.
J Clin Med. 2022 Dec 2;11(23):7169. doi: 10.3390/jcm11237169.
The hexanic extract of (HESr) has been in use for decades as an effective, safe and well-tolerated therapy for relieving bothersome lower urinary tract symptoms (LUTS) associated with benign prostate hyperplasia (BPH). This manuscript gives an overview of HESr as monotherapy for LUTS/BPH treatment and focuses on the currently available literature investigating the possible clinical benefits of HESr combination therapy with α-blockers. Combination therapy of HESr with α-blockers has been gaining significant interest in recent years, as an increasing body of evidence shows the beneficial pharmacological effects that HESr treatment can add to standard first-line treatment with α-blockers. By reducing persistent Prostatic Inflammatory Status (PIS), commonly present in LUTS/BPH patients, HESr complements the relaxation of prostate smooth muscle induced by α-blockers, thus providing additional symptom relief. Data suggest that patients harbouring PIS and having a specific clinical profile might especially benefit from the combination therapy. Future therapeutic efforts may take advantage of more personalised strategies for LUTS/BPH management.
几十年来，[具体植物名称]的己烷提取物（HESr）一直作为一种有效、安全且耐受性良好的疗法，用于缓解与良性前列腺增生（BPH）相关的令人烦恼的下尿路症状（LUTS）。本文综述了HESr作为LUTS/BPH单一疗法的情况，并重点关注了目前有关HESr与α受体阻滞剂联合治疗可能的临床益处的文献。近年来，HESr与α受体阻滞剂的联合治疗越来越受到关注，因为越来越多的证据表明HESr治疗可以为α受体阻滞剂的标准一线治疗增添有益的药理作用。通过减轻LUTS/BPH患者中常见的持续性前列腺炎症状态（PIS），HESr补充了α受体阻滞剂诱导的前列腺平滑肌松弛作用，从而进一步缓解症状。数据表明，患有PIS且具有特定临床特征的患者可能尤其受益于联合治疗。未来的治疗努力可能会利用更个性化的策略来管理LUTS/BPH。
